HCPCS code J1322: Elosulfase alfa billing guide

Key takeaways

HCPCS code J1322 covers injection, elosulfase alfa, 1 mg, the enzyme replacement drug sold as Vimizim.

One billable unit equals 1 mg, so a 2 mg/kg weekly dose makes units scale with the patient’s body weight.

Vimizim ships in 5 mg single-dose vials, so most doses leave a few discarded milligrams to report on a separate JW line.

Pair J1322 with E76.210 for Morquio A syndrome, report the 11-digit NDC, and confirm the prior authorization is still active.

Practice management software like Pabau keeps the weight, dose, and vial record attached to the claim, so unit errors surface before submission.

HCPCS code J1322 is the Healthcare Common Procedure Coding System Level II code for injection, elosulfase alfa, 1 mg. Elosulfase alfa is the enzyme replacement therapy sold as Vimizim by BioMarin. It treats Mucopolysaccharidosis type IVA, better known as Morquio A syndrome. One billable unit equals 1 mg of drug administered.

That one-milligram definition is what makes J1322 awkward to bill. The labeled dose is weight-based, so the unit count on the claim moves as the patient grows. A 15 kg child and a 45 kg teenager on the same weekly schedule generate very different claim lines. Elosulfase alfa also carries a high list price, so a single miscounted line is worth thousands of dollars.

One correction before the detail. J1322 is widely quoted as an epinephrine code, and it is not. Injectable epinephrine sits in an entirely different code family, which changed on July 1, 2025. There is a section on that below, because the mix-up puts real claims on the wrong line.

What HCPCS code J1322 covers

J1322 covers the drug itself, not the act of infusing it. The official descriptor is Injection, elosulfase alfa, 1 mg. It sits in the J-code series that CMS maintains under HCPCS Level II for non-oral drugs. Payers match claim lines against that exact descriptor, so a billing system carrying stale wording can trigger an invalid-code rejection.

Elosulfase alfa replaces N-acetylgalactosamine-6-sulfatase, the enzyme missing in Morquio A syndrome. Without it, keratan sulfate builds up in bone, cartilage, and connective tissue. The drug is a lifelong weekly intravenous infusion. That means the same patient generates a J1322 line roughly 52 times a year. That repetition is why a small unit error compounds fast.

The FDA prescribing information for Vimizim is the source your payer will fall back on in an audit. Keep the current label version on file alongside your billing policy. Descriptor and unit definitions should be re-checked against the annual CMS HCPCS Level II update, since J-code wording occasionally changes.

How to calculate J1322 units from a weight-based dose

Units equal milligrams administered. Because the labeled dose is 2 mg/kg, the unit count is simply the patient’s weight in kilograms multiplied by two. A 25 kg patient receives 50 mg, which is 50 units of J1322. There is no conversion factor to remember and no rounding to a vial size.

The harder half of the arithmetic is the vial. Vimizim comes in 5 mg single-dose vials, and most weight-based doses do not divide evenly by five. Whatever is left in the last vial is discarded drug, and CMS wants it reported. That means a second claim line, the discarded milligrams as units, and modifier JW.

The table below works the whole calculation through for five body weights. Run the same three steps for your own patient: dose, vials opened, discarded remainder.

Two practical points fall out of that table. First, weight determines the units, so the weight recorded on the date of service is a billing document. Using last quarter’s weight for a growing child understates the claim. Second, a patient whose dose lands on a multiple of five never generates a JW line. A patient sitting just above a multiple generates one nearly every week.

Medicare and payer coverage for elosulfase alfa

Elosulfase alfa is a clinician-administered infusion, so it is billed under the medical benefit rather than the pharmacy benefit. Medicare Part B covers it when it is furnished incident to a physician’s service in an office or outpatient setting. The record also has to show the drug is reasonable and necessary. Medicare Advantage plans generally require prior authorization, and many list J1322 on their Part B drug authorization file.

Payment follows the Average Sales Price methodology, which is ASP plus 6% for most Part B drugs. CMS republishes those figures every quarter in its ASP pricing files, so the payable amount per unit changes four times a year. Pull the current quarter’s file rather than reusing a rate from a paid claim. Vimizim’s list price runs to four figures per 5 mg vial, which puts a year of therapy for one patient in the high six figures.

Commercial and Medicaid coverage varies more. Most commercial plans publish a named medical policy for elosulfase alfa, and nearly all require authorization before the first infusion. Many also apply a site-of-care policy that steers stable patients from a hospital outpatient department to an infusion suite or the home. State Medicaid programs may follow ASP, a state drug fee schedule, or maximum allowable cost pricing. Verify the rate in the state portal before you bill.

Because this is lifelong therapy, the authorization is the thing that quietly breaks. Approvals are usually issued for six or twelve months and then need renewal with fresh clinical evidence. A weekly infusion schedule means an expired authorization can swallow four or five claims before anyone notices. Track the expiry date, not just the approval.

For practices juggling drug billing across several payer types, Pabau’s prescription management software keeps a payer-specific record against each administration event. Your team can see which plan approved what, and until when, without opening a spreadsheet.

Medical necessity criteria payers apply to Morquio A

Payer policies for elosulfase alfa are unusually consistent, because the drug has one approved indication and a rare-disease population. Most policies ask for the same short list before the first approval.

• Confirmed MPS IVA diagnosis: Reduced N-acetylgalactosamine-6-sulfatase enzyme activity on assay, or two pathogenic variants in the GALNS gene on genetic testing. A clinical impression alone rarely clears the review.
• Prescriber specialty: The order is written or co-signed by a geneticist, metabolic specialist, or another physician experienced in managing mucopolysaccharidoses.
• Dose within label: 2 mg/kg once weekly, calculated from a documented current weight. Doses above label usually need separate justification.
• Baseline function measures: Many policies want a starting endurance measure such as a six-minute walk test or a three-minute stair climb, plus baseline respiratory function.
• Safety setting: Evidence that infusions happen where anaphylaxis can be managed, which follows directly from the drug’s boxed warning.
• Response for renewal: At reauthorization, documentation that the patient is benefiting, usually through repeat endurance or respiratory measures and a clinical summary.

Collect those items once and reuse them. The baseline test results in particular tend to be requested again at every renewal, and re-running them because nobody saved the first set delays care.

ICD-10 diagnosis codes paired with J1322

The primary pairing for J1322 is E76.210, Morquio A mucopolysaccharidoses. That is the ICD-10-CM code that matches the approved indication, and it is the code most payer policies name outright. Everything else in the E76.2 family is either a different disease or a placeholder.

Morquio A patients usually carry a long comorbidity list, including skeletal and airway findings. Codes such as M41.9 for scoliosis or M48.02 for cervical spinal stenosis belong in the record and on the encounter where they were addressed. They do not establish necessity for the drug, so keep E76.210 in the primary position on the J1322 line.

Modifiers, NDC reporting, and administration codes

A complete J1322 claim has more moving parts than the drug line alone. These are the elements payers reject on most often.

• NDC on the drug line: Report the 11-digit National Drug Code in 5-4-2 format with leading zeros, which makes Vimizim’s 68135-100-01 read as 68135-0100-01. Use the N4 qualifier and the exact code from the carton you used.
• NDC quantity and unit of measure: The NDC quantity is reported in the drug’s own unit, which is milliliters for this solution. Vimizim is 1 mg per mL, so a 43 mg dose is 43 mL. The figures match here by coincidence of concentration, not as a general rule.
• Modifier JW: Report discarded drug from a single-dose vial on a separate claim line, with the discarded milligrams as units. CMS treats Vimizim as a single-dose container, so this applies whenever the last vial is not fully used.
• Modifier JZ: Append JZ to the drug line when nothing was discarded. It is an attestation, not a payment modifier, and leaving it off an unwasted claim can trigger an edit.
• Administration codes: The infusion is billed separately from the drug. Use 96365 for the first hour of intravenous infusion and 96366 for each additional hour. A 3.5 to 4.5 hour infusion usually supports two or three units of 96366.
• Premedication: The label suggests an antihistamine, with or without an antipyretic, 30 to 60 minutes before the infusion. Any premedication given has its own drug code, such as J1200 for injectable diphenhydramine, and its own administration sequencing rules.
• Place of service: Report where the infusion happened, using POS 11 for the office, POS 22 for hospital outpatient, or POS 12 for the home. Site-of-care policies attach to this field, so it is worth a second look.

CMS keeps its wastage and pricing guidance together in its Part B drugs materials, and individual Medicare Administrative Contractors may add local instructions. Check your contractor’s articles before you set a standing rule for JW and JZ.

Documentation requirements for J1322 claims

A J1322 claim is only as defensible as the infusion record behind it. Because the payable amount is large and the schedule is weekly, this code attracts post-payment review. Capture these at the time of the infusion rather than reconstructing them later.

• Diagnostic proof: The enzyme assay result or genetic test report confirming MPS IVA, filed on the patient record.
• Weight on the date of service: Recorded in kilograms, with the 2 mg/kg calculation shown. This is what supports the unit count.
• Drug detail: Milligrams administered, milliliters infused, number of vials opened, milligrams discarded, plus lot number and NDC from the carton.
• Infusion times: Start and stop times for the infusion. Without them, the units of 96366 cannot be supported on review.
• Premedication record: Drug, dose, route, and time given, since it explains any separately billed premedication line.
• Safety monitoring: Vital signs, the observation period, and any hypersensitivity reaction with how it was managed.
• Authorization trail: The prescriber’s order, the authorization number, and the approved date range for the course of therapy.

Practices tightening up their record-keeping should also review the HIPAA documentation standards that govern how these records are stored and shared. Pabau’s digital forms can be built to capture weight, dose, vial count, and lot number at the chair. Your billing team then codes from the record rather than a handwritten sheet. High-volume infusion services can see how IV therapy EMR software structures the same drug-to-code workflow.

J1322 vs. the other MPS enzyme replacement J-codes

Each mucopolysaccharidosis subtype has its own enzyme therapy and its own J-code. The descriptors look alike, the unit definitions do not, and the drugs are not interchangeable. A cross-coded claim in this family reads as an overpayment risk rather than a typo.

Cross-check the code against the current CMS HCPCS file each January. When a descriptor looks unfamiliar, check a reference such as the AAPC entry for J1322. Laronidase is the one worth flagging on a cheat sheet, because its 0.1 mg unit breaks the pattern the rest of the family follows.

Why J1322 is not an epinephrine code

J1322 has nothing to do with epinephrine, despite how often the two are linked online. The confusion is easy to explain. Elosulfase alfa carries a boxed warning for anaphylaxis, epinephrine is the treatment for anaphylaxis, and epinephrine’s old J-code sat close by in the numbering.

Injectable epinephrine was reported with J0171 until that code was deactivated on June 30, 2025. From July 1, 2025, brand and therapeutically equivalent products moved to J0165, described as injection, epinephrine, not otherwise specified, 0.1 mg. Single-source products moved to manufacturer-specific codes in the J0162 and J0166 to J0169 range.

That distinction matters at the infusion chair. Say a Morquio A patient reacts during an infusion and receives epinephrine. That drug goes on its own line under the current epinephrine code. It never goes on the J1322 line, and the elosulfase alfa units do not change because of it.

Common billing errors with J1322 and how to avoid them

Denials on this code cluster around a short list of mistakes. Most are caught by a pre-submission check that takes a minute per claim.

• Billing one unit per vial: A 5 mg vial is 5 units, not 1. Practices that bill by vial count understate a 43 mg dose as 9 units instead of 43, and lose most of the payment.
• Using a stale weight: Units follow the weight on the date of service. Pediatric patients outgrow last quarter’s dose, and the claim quietly stops matching the chart.
• Skipping the JW line: Discarded drug from a partly used vial has to be reported on its own line. Rolling waste into the administered units instead is a documentation mismatch waiting to be audited.
• Attaching JZ when there was waste: JZ attests that nothing was discarded. Using it as a default modifier contradicts your own infusion log.
• Pairing an unspecific diagnosis: E76.219 or E76.3 on a maintenance claim invites a medical necessity denial. Move to E76.210 once the subtype is confirmed.
• Cross-coding another MPS enzyme therapy: J1743, J1458, J1931, and J3397 are different drugs for different subtypes. Laronidase is billed in 0.1 mg units, so cross-coding also multiplies the unit error tenfold.
• Treating J1322 as epinephrine: Some code lists still repeat this error. Epinephrine belongs on the J0165 family of codes, and J1322 is elosulfase alfa only.
• Missing infusion stop time: Without a stop time, the additional-hour units of 96366 cannot be defended. The administration payment shrinks even when the drug line pays.
• Billing past the authorization: A weekly schedule burns through claims fast. Once an approval lapses, several infusions can be delivered before the first denial arrives.

How Pabau keeps weight-based drug claims consistent

In most practices, the numbers behind a J1322 claim start out scattered. The weight sits in the clinical note. The dose is calculated at the chair. Vial and lot detail land on a paper infusion sheet. Days later, someone in billing retypes all of it into a claim. Every hand-off is a chance for units and milligrams to drift apart.

Practice management software like Pabau keeps that chain in one place. The intake record, the treatment note, the infusion detail, and the invoice all hang off one patient timeline. Your coder reads the same numbers the nurse wrote. Pabau’s claims management software then carries those details onto the claim. It also tracks status through to payment. A rejected line comes back to a named person, not a shared inbox.

For a lifelong weekly therapy, the payoff is consistency week to week. The authorization dates, the current weight, and last week’s vial count are all where your team already works, so nobody hunts for them. Pabau’s practice management workflows also keep the audit trail intact if a payer asks for the file two years later.

The outcome is fewer surprises on the remittance. Unit mismatches surface within days of submission. You are not finding them a quarter later, after a dozen high-value claims went out the same way.

Keep every J1322 claim matched to the infusion record

Pabau links weight, dose, vial count, and lot number from the treatment note straight to the claim. Your team bills elosulfase alfa from the record instead of retyping it, and sees rejected lines in days rather than at quarter end.

Book a demo

Conclusion

J1322 is a small code with an outsized cost attached, and almost everything that goes wrong with it is arithmetic. Units equal milligrams, milligrams come from the current weight, and the leftover in the last 5 mg vial belongs on its own JW line. Get those three right and pair the claim with E76.210, and most denials never happen.

The rest is discipline over time. A weekly infusion means 52 chances a year to repeat the same mistake, so the fix is a process rather than a careful reviewer. Keep the weight, the vial count, and the authorization dates in the same system your clinical team already uses.

If you would like to see how the infusion record and the claim stay connected in one workflow, book a demo with our team.

Continue your research

Need the documentation behind a high-value drug claim to hold up? Medical forms at your healthcare practice shows how structured forms build an audit-ready administration record.

Billing another supply or drug code with its own unit rules? HCPCS code B4036 walks through coverage, modifiers, and documentation for a code billed on a recurring schedule.

Storing enzyme assay results and authorization letters on the patient record? HIPAA compliance for medical offices sets out the standards those records have to meet.

Frequently asked questions